Drug Trial Radar · NCT00549757
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)
Last checked: Nov 19, 2026Latest source record: Apr 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
8,606
Actual
Start
Oct 2007
Primary completion
Feb 2013
Study completion Feb 2013
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 26, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine whether, in patients with type 2 diabetes and pre-existing disease of the heart and the circulatory system and/or the kidney, aliskiren at a target dose of 300 mg once daily (compared to placebo), on top of conventional treatment, reduces death and disease caused by the heart, the circulatory system and the kidney. AMENDMENT 4 RATIONALE (MARCH 2012) : Protocol amendment 4 served to address the data monitoring committee recommendation dated 14 Dec 2011 to discontinue study treatment in all participating patients. It also addressed the subsequent Health Authorities request to implement a 12 month safety follow-up period (actual duration was 9 months in average) post study drug discontinuation.
Conditions
- Type 2 Diabetes Mellitus
- Cardiovascular Disease
Interventions
AliskirenDrug
Aliskiren 150 mg film-coated tablets
PlaceboDrug
Placebo to match aliskiren 150 mg film-coated tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Occurrence of Primary Composite Endpoint (Core : Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 months)
- Percentage of Participants With Cardiovascular (CV) Death (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 months)
- Percentage of Participants With Resuscitated Sudden Death (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 Months)
- Percentage of Participants With Fatal/Non-fatal Myocardial Infarction (MI) (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 Months)
- Percentage of Participants With Fatal/Non-fatal Stroke (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 Months)
- Percentage of Participants With Onset of End-stage Renal Disease (ESRD) (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 Months)
- Percentage of Participants With Doubling of Baseline Serum Creatinine Concentration, Sustained for at Least One Month (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 Months)
- Percentage of Participants With Unplanned Hospitalization for Heart Failure (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 Months)
- Percentage of Participants With All Cause Mortality (Core: Active Treatment Phase)Time frame: Time from randomization to the first event (Maximum 50 months)
- Percentage of Participants With Occurrence of Primary Composite Endpoint (Extension Phase)Time frame: From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)
- Percentage of Participants With Cardiovascular (CV) Death (Extension Phase)Time frame: from cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)
- Percentage of Participants With Resuscitated Sudden Death (Extension Phase)Time frame: From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)
- Percentage of Participants Fatal/Non-fatal Myocardial Infarction (MI) (Extension Phase)Time frame: From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 month in average)
- Percentage of Participants With Fatal/Non-fatal Stroke (Extension Phase)Time frame: From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)
- Percentage of Participants With Onset of End-stage Renal Disease (ESRD) (Extension Phase)Time frame: From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)
- Percentage of Participants Doubling of Baseline Serum Creatinine Concentration, Sustained for at Least One Month (Extension Phase)Time frame: From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)
- Percentage of Participants With Unplanned Hospitalization for Heart Failure (Extension Phase)Time frame: From cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)
- Percentage of Participants With All Cause Mortality (Extension Phase)Time frame: from cut-off date (20Dec2011/End of Treatment (EOT) ) to the first event after cut-off date (9 months in average)
Locations
776 sites in 37 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Huntsville, Alabama
Novartis Investigative Site
Mobile, Alabama
Novartis Investigative Site
Mobile, Alabama
Novartis Investigative Site
Montgomery, Alabama
Novartis Investigative Site
Muscle Shoals, Alabama
Novartis Investigative Site
Peoria, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Fayetteville, Arkansas
Novartis Investigative Site
Burlingame, California
Novartis Investigative Site
Fullerton, California
Novartis Investigative Site
Huntington Beach, California
Novartis Investigative Site
Oakland, California
Novartis Investigative Site
Pasadena, California
Novartis Investigative Site
Riverside, California
Novartis Investigative Site
Spring Valley, California
Novartis Investigative Site
Torrance, California
Novartis Investigative Site
Walnut Creek, California
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
Bridgeport, Connecticut
Novartis Investigative Site
Aventura, Florida
Novartis Investigative Site
Boca Raton, Florida
Novartis Investigative Site
Fort Lauderdale, Florida
Novartis Investigative Site
Hollywood, Florida
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Lauderdale Lakes, Florida
Novartis Investigative Site
Pensacola, Florida
Novartis Investigative Site
Plantation, Florida
Novartis Investigative Site
West Palm Beach, Florida
Novartis Investigative Site
Atlanta, Georgia
Novartis Investigative Site
Augusta, Georgia
Novartis Investigative Site
Augusta, Georgia
Novartis Investigative Site
Cumming, Georgia
Novartis Investigative Site
Honolulu, Hawaii
Showing 40 of 776 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.